209 related articles for article (PubMed ID: 31429028)
1. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
Park SI; Lin CP; Ren N; Angus SP; Dittmer DP; Foote M; Parton T; Bhatt AP; Fedoriw YD; Roth DP; Cann ML; Johnson GL; Damania B
Target Oncol; 2019 Oct; 14(5):563-575. PubMed ID: 31429028
[TBL] [Abstract][Full Text] [Related]
2. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
[No Abstract] [Full Text] [Related]
3. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
[TBL] [Abstract][Full Text] [Related]
4. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
[TBL] [Abstract][Full Text] [Related]
5. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.
Mahadevan D; Morales C; Cooke LS; Manziello A; Mount DW; Persky DO; Fisher RI; Miller TP; Qi W
PLoS One; 2014; 9(6):e95184. PubMed ID: 24893165
[TBL] [Abstract][Full Text] [Related]
6. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
[No Abstract] [Full Text] [Related]
7. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
[TBL] [Abstract][Full Text] [Related]
8. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN
Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.
Wang L; Arras J; Katsha A; Hamdan S; Belkhiri A; Ecsedy J; El-Rifai W
Mol Oncol; 2017 Aug; 11(8):981-995. PubMed ID: 28417568
[TBL] [Abstract][Full Text] [Related]
10. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P
Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033
[TBL] [Abstract][Full Text] [Related]
12. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Görgün G; Calabrese E; Hideshima T; Ecsedy J; Perrone G; Mani M; Ikeda H; Bianchi G; Hu Y; Cirstea D; Santo L; Tai YT; Nahar S; Zheng M; Bandi M; Carrasco RD; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Jun; 115(25):5202-13. PubMed ID: 20382844
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
[TBL] [Abstract][Full Text] [Related]
14. Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma.
Yen CC; Chen SC; Hung GY; Wu PK; Chua WY; Lin YC; Yen CH; Chen YC; Wang JY; Yang MH; Chao Y; Chang MC; Chen WM
Int J Oncol; 2019 Oct; 55(4):938-948. PubMed ID: 31485600
[TBL] [Abstract][Full Text] [Related]
15. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE
Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633
[TBL] [Abstract][Full Text] [Related]
16. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D; Pettengell R
Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
[TBL] [Abstract][Full Text] [Related]
17. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
[TBL] [Abstract][Full Text] [Related]
18. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
19. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
[TBL] [Abstract][Full Text] [Related]
20. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
